Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Total Liabilities (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Total Liabilities for 11 consecutive years, with $37.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities changed N/A to $37.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $37.3 million, a N/A change, with the full-year FY2025 number at $37.3 million, changed N/A from a year prior.
  • Total Liabilities was $37.3 million for Q4 2025 at Crescent Biopharma, up from $21.6 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $37.3 million in Q4 2025 to a low of $2.6 million in Q1 2025.
  • A 5-year average of $11.0 million and a median of $8.9 million in 2022 define the central range for Total Liabilities.
  • Biggest YoY gain for Total Liabilities was 400.43% in 2025; the steepest drop was 50.57% in 2025.
  • Crescent Biopharma's Total Liabilities stood at $12.7 million in 2021, then plummeted by 30.31% to $8.9 million in 2022, then decreased by 22.28% to $6.9 million in 2023, then tumbled by 37.38% to $4.3 million in 2024, then surged by 762.62% to $37.3 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Total Liabilities are $37.3 million (Q4 2025), $21.6 million (Q3 2025), and $18.2 million (Q2 2025).